Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 2,300 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,623 shares of the company’s stock after acquiring an additional 2,300 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Neurocrine Biosciences were worth $7,593,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of NBIX. Golden State Wealth Management LLC bought a new position in Neurocrine Biosciences during the fourth quarter worth about $25,000. Brooklyn Investment Group raised its stake in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the period. Blue Trust Inc. boosted its position in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. R Squared Ltd bought a new position in Neurocrine Biosciences during the fourth quarter worth $61,000. Finally, UMB Bank n.a. increased its holdings in shares of Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 1,551 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total value of $181,125.78. Following the sale, the insider now owns 19,544 shares in the company, valued at $2,282,348.32. This trade represents a 7.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44. Following the transaction, the director now owns 517,030 shares of the company’s stock, valued at $79,064,227.60. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 236,600 shares of company stock worth $34,348,261 over the last 90 days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $119.11 on Tuesday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The stock has a market capitalization of $11.88 billion, a price-to-earnings ratio of 36.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. The company’s 50 day simple moving average is $136.35 and its 200 day simple moving average is $129.11.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences announced that its Board of Directors has authorized a share repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

NBIX has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 11th. They set a “hold” rating and a $138.00 target price for the company. Barclays boosted their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Guggenheim reduced their price target on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.